{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:48:48Z","timestamp":1790380128103,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Systemic sirolimus (SS) is an mTOR inhibitor used in the management of pediatric intraluminal pulmonary vein stenosis (PVS). SS initiation, monitoring, including patient compliance with toxicity surveillance, and potential adverse events (AE) in PVS patients are under reported. A single-center retrospective cohort study of consecutive patients who were initiated on SS for PVS from January 1, 2020 to December 31, 2024 was performed. Fifty patients with a median age of 7\u00a0months (range 2\u2013165) received SS for PVS (median number of stenotic veins;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093 (1\u20134)) for a median duration of 18\u00a0months (1\u201360). The median time to therapeutic level was 9\u00a0days [IQR 3, 20] with two never achieving therapeutic values. In patients who received SS for at least 6\u00a0months (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939), the median number of blood draws and number of dose adjustments in the first 6\u00a0months were 14 [IQR 5, 27] and 3 [1, 7], respectively. Most levels among patients (75%; [IQR 64, 84]) did not require a dose adjustment. Toxicity surveillance compliance increased from 58% [IQR 42, 83] to 79% [IQR 62.5, 92] (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.22) following transitioning ownership of SS management to a dedicated PVS team. Eighteen percent (9\/50) of patients had an AE potentially related to SS; SS was discontinued in three. PVS patients receiving SS have high, but variable rates of therapeutic levels and SS discontinuation due to AEs is uncommon. Compliance with safety labs may improve with ownership by a dedicated monitoring team.\n                  <\/jats:p>","DOI":"10.1007\/s00246-025-04038-6","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:18:41Z","timestamp":1759335521000},"page":"2615-2621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Sirolimus Monitoring in Pediatric Pulmonary Vein Stenosis"],"prefix":"10.1007","volume":"47","author":[{"given":"Heather","family":"Meluskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Blowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Rome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Avitabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine D.","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"22","key":"4038_CR1","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.jacc.2021.04.013","volume":"77","author":"JD Patel","year":"2021","unstructured":"Patel JD, Briones M, Mandhani M et al (2021) Systemic sirolimus therapy for infants and children with pulmonary vein stenosis. J Am Coll Cardiol 77(22):2807\u20132818","journal-title":"J Am Coll Cardiol"},{"key":"4038_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpeds.2018.01.029","volume":"198","author":"R Callahan","year":"2018","unstructured":"Callahan R, Kieran MW, Baird CW et al (2018) Adjunct targeted biologic inhibition agents to treat aggressive multivessel intraluminal pediatric pulmonary vein stenosis. J Pediatr 198:29-35.e5","journal-title":"J Pediatr"},{"issue":"12","key":"4038_CR3","doi-asserted-by":"publisher","first-page":"101401","DOI":"10.1016\/j.jacadv.2024.101401","volume":"3","author":"AB Kalustian","year":"2024","unstructured":"Kalustian AB, Hagan JL, Brlecic PE et al (2024) Systemic sirolimus therapy is associated with reduced intervention frequency in pulmonary vein stenosis. JACC Adv 3(12):101401","journal-title":"JACC Adv"},{"issue":"2","key":"4038_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00246-019-02253-6","volume":"41","author":"R Callahan","year":"2020","unstructured":"Callahan R, Esch JJ, Wang G, Ireland CM, Gauvreau K, Jenkins KJ (2020) Systemic sirolimus to prevent in-stent stenosis in pediatric pulmonary vein stenosis. Pediatr Cardiol 41(2):282\u2013289","journal-title":"Pediatr Cardiol"},{"issue":"5","key":"4038_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00246-023-03102-3","volume":"44","author":"MJ Shorofsky","year":"2023","unstructured":"Shorofsky MJ, Morgan GJ, Mejia E et al (2023) Management of complex pulmonary vein stenosis at altitude combining comprehensive percutaneous interventional treatment with sirolimus, pulmonary hypertension medications and intraluminal imaging with optical coherence tomography. Pediatr Cardiol 44(5):1125\u20131134","journal-title":"Pediatr Cardiol"},{"key":"4038_CR6","unstructured":"National Institute of Cancer. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US Department of Health and Human Services. Published online 2017:0\u2013155."},{"issue":"3","key":"4038_CR7","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.19102\/icrm.2017.080302","volume":"8","author":"J Reiffel","year":"2017","unstructured":"Reiffel J (2017) Time in the therapeutic range (TTR): an overly simplified conundrum. J Innov Card Rhythm Manage 8(3):2643\u20132646","journal-title":"J Innov Card Rhythm Manage"},{"key":"4038_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89027-X","author":"A Macdonald","year":"2000","unstructured":"Macdonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. https:\/\/doi.org\/10.1016\/S0149-2918(00)89027-X","journal-title":"Clin Ther"},{"issue":"4 Suppl 2","key":"4038_CR9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1053\/ajkd.2001.27838","volume":"38","author":"RB Ettenger","year":"2001","unstructured":"Ettenger RB, Grimm EM (2001) Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 38(4 Suppl 2):S22\u2013S28","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"4038_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s00246-020-02381-4","volume":"41","author":"K Sivakumar","year":"2020","unstructured":"Sivakumar K, Pavithran S, Sonawane B, Rajendran M, Ramasamy R (2020) Serum sirolimus levels after implantation of third generation drug eluting cobalt chromium coronary stent in Ductus Arteriosus in neonates with duct-dependent pulmonary circulation. Pediatr Cardiol 41(7):1354\u20131362","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"4038_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1017\/S104795112200110X","volume":"33","author":"HKN Kurup","year":"2023","unstructured":"Kurup HKN, Gopalakrishnan A, Sasikumar D, Krishnamoorthy KM (2023) Safety of drug-eluting stents for stenting patent arterial duct in neonates. Cardiol Young 33(3):437\u2013443","journal-title":"Cardiol Young"},{"issue":"2","key":"4038_CR12","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","volume":"137","author":"DM Adams","year":"2016","unstructured":"Adams DM, Trenor CC III, Hammill AM et al (2016) Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 137(2):e20153257","journal-title":"Pediatrics"},{"issue":"1","key":"4038_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/TP.0b013e3181aad256","volume":"88","author":"RT Neff","year":"2009","unstructured":"Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC (2009) Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 88(1):135\u2013141","journal-title":"Transplantation"},{"issue":"1","key":"4038_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30758","volume":"71","author":"R Kalbfell","year":"2024","unstructured":"Kalbfell R, Cohen-Cutler S, Grisham E et al (2024) Infectious complications of vascular anomalies treated with sirolimus: a systematic review. Pediatr Blood Cancer 71(1):e30758","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"4038_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1159\/000533675","volume":"239","author":"M Navarro","year":"2023","unstructured":"Navarro M, Allemang-Trivalle A, Leducq S et al (2023) Indication for a Pneumocystis prophylaxis therapy in patients with vascular anomalies treated with PIK3\/AKT\/mTOR pathway inhibitors: experts\u2019 opinion and systematic review from the literature. Dermatology 239(6):942\u2013951","journal-title":"Dermatology"},{"issue":"6","key":"4038_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","volume":"94","author":"B Nashan","year":"2012","unstructured":"Nashan B, Citterio F (2012) Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 94(6):547\u2013561","journal-title":"Transplantation"},{"issue":"8","key":"4038_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jpedsurg.2022.11.009","volume":"58","author":"SC Mehl","year":"2023","unstructured":"Mehl SC, Whitlock RS, Ortega RM et al (2023) No association of sirolimus with wound complications in children with vascular anomalies. J Pediatr Surg 58(8):1555\u20131559","journal-title":"J Pediatr Surg"},{"issue":"5","key":"4038_CR18","volume":"1","author":"R Callahan","year":"2022","unstructured":"Callahan R, Morray BH, Hirsch R, Petit CJ (2022) Management of pediatric pulmonary vein stenosis. J Soc Cardiovasc Angiogr Interv 1(5):100391","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"4038_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/children8090783","author":"M Niccum","year":"2021","unstructured":"Niccum M, Callahan R, Gauvreau K, Jenkins KJ (2021) Aspiration is associated with poor treatment response in pediatric pulmonary vein stenosis. Children. https:\/\/doi.org\/10.3390\/children8090783","journal-title":"Children"},{"issue":"1","key":"4038_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/children8010019","volume":"8","author":"C Choi","year":"2021","unstructured":"Choi C, Gauvreau K, Levy P, Callahan R, Jenkins KJ, Chen M (2021) Longer exposure to left-to-right shunts is a risk factor for pulmonary vein stenosis in patients with Trisomy 21. Children 8(1):19","journal-title":"Children"},{"key":"4038_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/children8090729","author":"PE Hammer","year":"2021","unstructured":"Hammer PE, McEnaney K, Callahan R, Baird CW, Hoganson DM, Jenkins KJ (2021) The role of elevated wall shear stress in progression of pulmonary vein stenosis: evidence from two case studies. Children (Basel). https:\/\/doi.org\/10.3390\/children8090729","journal-title":"Children (Basel)"},{"key":"4038_CR22","first-page":"e015002","volume":"14","author":"R Callahan","year":"2025","unstructured":"Callahan R, Gauvreau K, Keochakian M et al (2025) Predicting outcomes in pediatric intraluminal pulmonary vein stenosis using a comprehensive standardized catheterization assessment: a prospective study. Circ Cardiovasc Interv 14:e015002","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-04038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-025-04038-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-04038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:07:42Z","timestamp":1787324862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-025-04038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4038"],"URL":"https:\/\/doi.org\/10.1007\/s00246-025-04038-6","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}